1
|
Arii S, Monden K, Niwano M, et al: Results
of surgical treatment for recurrent hepatocellular carcinoma;
comparison of outcome among patients with multicentric
carcinogenesis, intrahepatic metastasis, and extrahepatic
recurrence. J Hepatobiliary Pancreat Surg. 5:86–92. 1998.
View Article : Google Scholar
|
2
|
Llovet JM, Ricci S, Mazzaferro V, et al:
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med.
359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
3
|
Kudo M and Okanoue T: Management of
hepatocellular carcinoma in Japan: consensus-based clinical
practice manual proposed by the Japan Society of Hepatology.
Oncology. 72(Suppl 1): S2–S15. 2007. View Article : Google Scholar : PubMed/NCBI
|
4
|
Chung YH, Song IH, Song BC, et al:
Combined therapy consisting of intraarterial cisplatin infusion and
systemic interferon-alpha for hepatocellular carcinoma patients
with major portal vein thrombosis or distant metastasis. Cancer.
88:1986–1991. 2000. View Article : Google Scholar
|
5
|
Kaneko S, Urabe T and Kobayashi S:
Combination chemotherapy for advanced hepatocellular carcinoma
complicated by major portal vein thrombosis. Oncology. 62(Suppl 1):
S69–S73. 2002. View Article : Google Scholar
|
6
|
Patt YZ, Hassan MM, Lozano RD, et al:
Phase II trial of systemic continuous fluorouracil and subcutaneous
recombinant interferon Alfa-2b for treatment of hepatocellular
carcinoma. J Clin Oncol. 21:421–427. 2003. View Article : Google Scholar : PubMed/NCBI
|
7
|
Obi S, Yoshida H, Toune R, et al:
Combination therapy of intra-arterial 5-fluorouracil and systemic
interferon-alpha for advanced hepatocellular carcinoma with portal
venous invasion. Cancer. 106:1990–1997. 2006. View Article : Google Scholar
|
8
|
Uka K, Aikata H, Takaki S, et al: Similar
effects of recombinant interferon-alpha-2b and natural
interferon-alpha when combined with intra-arterial 5-fluorouracil
for the treatment of advanced hepatocellular carcinoma. Liver Int.
27:1209–1216. 2007.
|
9
|
Sakon M, Nagano H, Dono K, et al: Combined
intraarterial 5-fluorouracil and subcutaneous interferon-α therapy
for advanced hepatocellular carcinoma with tumor thrombi in the
major portal branches. Cancer. 94:435–442. 2002.
|
10
|
Ota H, Nagano H, Sakon M, et al: Treatment
of hepatocellular carcinoma with major portal vein thrombosis by
combined therapy with subcutaneous interferon-alpha and
intra-arterial 5-fluorouracil; role of type 1 interferon receptor
expression. Br J Cancer. 93:57–64. 2005.
|
11
|
Nagano H, Wada H, Kobayashi S, et al:
Long-term outcome of combined subcutaneous interferon-α and
intra-arterial 5-fluorouracil treatment for advanced hepatocellular
carcinoma with major portal vein thrombosis. Oncology. (In
Press).
|
12
|
Eguchi H, Nagano H, Yamamoto H, et al:
Augmentation of antitumor activity of 5-fluorouracil by interferon
alpha is associated with up-regulation of p27Kip1 in human
hepatocellular carcinoma cells. Clin Cancer Res. 6:2881–2890.
2000.
|
13
|
Yamamoto T, Nagano H, Sakon M, et al:
Partial contribution of tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to
anti-tumor effects of interferon-alpha/5-fluorouracil against
hepatocellular carcinoma. Clin Cancer Res. 10:7884–7895. 2004.
View Article : Google Scholar
|
14
|
Kondo M, Nagano H, Wada H, et al:
Combination of IFN-alpha and 5-fluorouracil induces apoptosis
through IFN-alpha/beta receptor in human hepatocellular carcinoma
cells. Clin Cancer Res. 11:1277–1286. 2005.PubMed/NCBI
|
15
|
Nakamura M, Nagano H, Sakon M, et al: Role
of the Fas/FasL pathway in combination therapy with
interferon-alpha and fluorouracil against hepatocellular carcinoma
in vitro. J Hepatol. 46:77–88. 2007. View Article : Google Scholar : PubMed/NCBI
|
16
|
Noda T, Nagano H, Takemasa I, et al:
Activation of Wnt/beta-catenin signalling pathway induces
chemoresistance to interferon-alpha/5-fluorouracil combination
therapy for hepatocellular carcinoma. Br J Cancer. 100:1647–1658.
2009. View Article : Google Scholar : PubMed/NCBI
|
17
|
Wada H, Nagano H, Yamamoto H, et al:
Combination of interferon-alpha and 5-fluorouracil inhibits
endothelial cell growth directly and by regulation of angiogenic
factors released by tumor cells. BMC Cancer. 9:361–372. 2009.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Tomimaru Y, Eguchi H, Wada H, et al:
Insulin-like growth factor-binding protein 7 alters the aensitivity
to interferon-based anticancer therapy in hepatocellular carcinoma
cells. Br J Cancer. 102:1483–1490. 2010. View Article : Google Scholar : PubMed/NCBI
|
19
|
Tomimaru Y, Eguchi H, Nagano H, et al:
MicroRNA-21 induces resistance to the anti-tumor effect of
interferon-α/5-fluorouracil in hepatocellular carcinoma cells. Br J
Cancer. 103:1617–1626. 2010.PubMed/NCBI
|
20
|
Nagano H, Sakon M, Eguchi H, et al:
Hepatic resection followed by IFN-alpha and 5-FU for advanced
hepatocellular carcinoma with tumor thrombus in the major portal
branch. Hepatogastroenterology. 54:172–179. 2007.PubMed/NCBI
|
21
|
Nagano H, Miyamoto A, Wada H, et al:
Interferon-α and 5-fluorouracil combination therapy following
palliative hepatic resection in patients with advanced
hepatocellular carcinoma, portal venous tumor thrombus in the major
trunk and multiple nodules. Cancer. 110:2493–2501. 2007.
|
22
|
The General Rules for the Clinical and
Pathological Study of Primary Liver Cancer. 5th edition. Liver
Cancer Study Group of Japan; 2008
|
23
|
Oken MM, Creech RH, Tormey DC, et al:
Toxicity and response criteria of the Eastern Cooperative Oncology
Group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
24
|
Kaplan EL and Meier P: Nonparametric
estimation from incomplete observations. J Am Stat Assoc.
53:457–481. 1958. View Article : Google Scholar
|
25
|
Ikai I, Arii S, Ichida T, et al: Report of
the 16th follow-up survey of primary liver cancer. The Liver Cancer
Study Group of Japan Hepatol Res. 32:163–172. 2005.PubMed/NCBI
|
26
|
Yamakado K, Tanaka N, Nakatsuka A, et al:
Clinical efficacy of portal vein stent placement in patients with
hepatocellular carcinoma invading the main portal vein. J Hepatol.
30:660–668. 1999. View Article : Google Scholar : PubMed/NCBI
|
27
|
Cancer of the Liver Italian Program (CLIP)
investigators: A new prognostic system for hepatocellular
carcinoma: a retrospective study of 435 patients. Hepatology.
28:751–755. 1998. View Article : Google Scholar : PubMed/NCBI
|
28
|
Asahara T, Itamoto T, Katayama K, et al:
Hepatic resection with tumor thrombectomy for hepatocellular
carcinoma with tumor thrombi in the major vasculature.
Hepatogastroenterology. 46:1862–1869. 1999.PubMed/NCBI
|
29
|
Ohkubo T, Yamamoto J, Sugawara Y, et al:
Surgical results for hepatocellular carcinoma with macroscopic
portal vein thrombosis. J Am Coll Surg. 191:657–660. 2000.
View Article : Google Scholar : PubMed/NCBI
|
30
|
Furuse J, Iwasaki M, Yoshino M, et al:
Hepatocellular carcinoma with portal vein tumor thrombus:
embolization of arterioportal shunts. Radiology. 204:787–790. 1997.
View Article : Google Scholar : PubMed/NCBI
|
31
|
Lee HS, Kim JS, Choi IJ, et al: The safety
and efficacy of trans-catheter arterial chemoembolization in the
treatment of patients with hepatocellular carcinoma and main portal
vein obstruction: a prospective controlled study. Cancer.
79:2087–2094. 1997. View Article : Google Scholar : PubMed/NCBI
|
32
|
Poon RT, Ng KK, Lam CM, et al: Learning
curve for radio-frequency ablation of liver tumors: prospective
analysis of initial 100 patients in a tertiary institution. Ann
Surg. 239:441–449. 2004.PubMed/NCBI
|
33
|
Mazzaferro V, Regalia E, Doci R, et al:
Liver transplantation for the treatment of small hepatocellular
carcinomas in patients with cirrhosis. N Engl J Med. 334:693–700.
1996. View Article : Google Scholar : PubMed/NCBI
|
34
|
Poon RT, Fan ST, Ng IO and Wong J:
Prognosis after hepatic resection for stage IVA hepatocellular
carcinoma: a need for reclassification. Ann Surg. 237:376–383.
2003. View Article : Google Scholar : PubMed/NCBI
|
35
|
Ikai I, Yamaoka Y, Yamamoto Y, et al:
Surgical intervention for patients with stage IV-A hepatocellular
carcinoma without lymph node metastasis proposal as a standard
therapy. Ann Surg. 227:433–439. 1998. View Article : Google Scholar : PubMed/NCBI
|
36
|
Shi J, Lai ECH, Li N, et al: Surgical
treatment for hepatocellular carcinoma with portal vein tumor
thrombus. Ann Surg Oncol. 17:2073–2080. 2010. View Article : Google Scholar : PubMed/NCBI
|
37
|
Tazawa J, Maeda M, Sakai Y, et al:
Radiation therapy in combination with transcatheter arterial
chemoembolization for hepatocellular carcinoma with extensive
portal vein involvement. J Gastroenterol Hepatol. 16:660–665. 2001.
View Article : Google Scholar : PubMed/NCBI
|
38
|
Ishikura S, Ogino T, Furuse J, et al:
Radiotherapy after transcatheter arterial chemoembolization for
patients with hepatocellular carcinoma and portal vein tumor
thrombus. Am J Clin Oncol. 25:189–193. 2002. View Article : Google Scholar : PubMed/NCBI
|
39
|
Minagawa M, Makuuchi M, Takayama T and
Ohtomo K: Selection criteria for hepatectomy in patients with
hepatocellular carcinoma and portal vein tumor thrombus. Ann Surg.
233:379–384. 2001. View Article : Google Scholar : PubMed/NCBI
|
40
|
Peng BG, He Q, Li JP and Zhou F: Adjuvant
transcatheter arterial chemoembolization improves efficacy of
hepatectomy for patients with hepatocellular carcinoma and portal
vein tumor thrombus. Am J Surg. 198:313–318. 2009. View Article : Google Scholar
|
41
|
Nakamura M, Nagano H, Marubashi S, et al:
A pilot study of combination chemotherapy of S-1, a novel oral DPD
inhibitor, and interferon-alpha for advanced hepatocellular
carcinoma with extrahepatic metastasis. Cancer. 112:1765–1771.
2008. View Article : Google Scholar
|
42
|
Llovet JM and Bruix J: Molecular targeted
therapies in hepatocellular carcinoma. Hepatology. 48:1312–1327.
2008. View Article : Google Scholar : PubMed/NCBI
|
43
|
Yang ZF, Poon RT, Liu Y, et al: High doses
of tyrosine kinase inhibitor PTK787 enhance the efficacy of
ischemic hypoxia for the treatment of hepatocellular carcinoma:
dual effects on cancer cell and angiogenesis. Mol Cancer Ther.
5:2261–2270. 2006. View Article : Google Scholar : PubMed/NCBI
|
44
|
Zhu AX, Sahani DV, Duda DG, et al:
Efficacy, safety, and potential biomarkers of sunitinib monotherapy
in advanced hepatocellular carcinoma: a phase II study. J Clin
Oncol. 27:3027–3035. 2009. View Article : Google Scholar : PubMed/NCBI
|
45
|
Murakami M, Kobayashi S, Marubashi S, et
al: Tyrosine kinase inhibitor PTK/ZK enhances the anti-tumor
effects of interferon-α/5-fluorouracil therapy for hepatocellular
carcinoma cells. Ann Surg Oncol. 18:589–596. 2011.PubMed/NCBI
|